Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sight Sciences, Inc. - Common Stock (NQ:SGHT)

6.455 +0.635 (+10.91%)
Streaming Delayed Price Updated: 1:04 PM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sight Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Sight Sciences (SGHT) Q3 2025 Earnings Transcript
Sight Sciences (SGHT) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property World Trade
Earnings Scheduled For November 6, 2025
 
Via Benzinga
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Breaking Down Sight Sciences: 6 Analysts Share Their Views
 
Via Benzinga
Which stocks are gapping on Friday?
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
UnitedHealthcare Adds Sight Sciences OMNI System To Covered Glaucoma Surgery Procedures
UnitedHealthcare's new policy covers implant-free glaucoma surgeries like OMNI, supporting treatment for mild to moderate open-angle glaucoma and cataracts. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Sight Sciences
 
Via Benzinga
The Analyst Verdict: Sight Sciences In The Eyes Of 4 Experts
 
Via Benzinga
These stocks are moving in today's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
What 6 Analyst Ratings Have To Say About Sight Sciences
 
Via Benzinga
Expert Outlook: Sight Sciences Through The Eyes Of 5 Analysts
 
Via Benzinga
These stocks are moving in today's pre-market session
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
Earnings Scheduled For March 5, 2025
 
Via Benzinga
Where Sight Sciences Stands With Analysts
 
Via Benzinga
Sight Sciences: Q4 Earnings Insights
 
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing In November
 
Via Benzinga
SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024
SGHT stock results show that Sight Sciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic this morning as we check out all of the biggest news worth reading about on Wednesday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Sight Sciences's Earnings: A Preview
 
Via Benzinga
Where Sight Sciences Stands With Analysts
 
Via Benzinga
SGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023
SGHT stock results show that Sight Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.